| Recent advances in targeted therapies in acute myeloid leukemia RS Bhansali, KW Pratz, C Lai Journal of Hematology & Oncology 16 (1), 29, 2023 | 118 | 2023 |
| DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3 BJ Thompson, R Bhansali, L Diebold, DE Cook, L Stolzenburg, ... Journal of Experimental Medicine 212 (6), 953-970, 2015 | 93 | 2015 |
| Lithium and therapeutic targeting of GSK-3 ME Snitow, RS Bhansali, PS Klein Cells 10 (2), 255, 2021 | 92 | 2021 |
| The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome P Lee, R Bhansali, S Izraeli, N Hijiya, JD Crispino Leukemia 30 (9), 1816-1823, 2016 | 91 | 2016 |
| DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3 RS Bhansali, M Rammohan, P Lee, AP Laurent, Q Wen, P Suraneni, ... The Journal of Clinical Investigation 131 (1), 2021 | 73 | 2021 |
| The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target M Rammohan, E Harris, RS Bhansali, E Zhao, LS Li, JD Crispino Oncogene 41 (14), 2003-2011, 2022 | 45 | 2022 |
| Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL J Zurko, I Nizamuddin, N Epperla, K David, JB Cohen, TK Moyo, T Ollila, ... Blood Advances 7 (12), 2657-2669, 2023 | 33 | 2023 |
| Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1A C Fruit, F Couly, R Bhansali, M Rammohan, MF Lindberg, JD Crispino, ... Pharmaceuticals 12 (4), 185, 2019 | 15 | 2019 |
| Efficacy and safety of chimeric antigen receptor T-cell therapy for relapsed/refractory immunoglobulin D multiple myeloma W Chen, Y Wang, K Qi, M Shi, J Cao, R Bhansali, X Wang, Y Liu, H Li, ... Transplantation and Cellular Therapy 27 (3), 273. e1-273. e5, 2021 | 14 | 2021 |
| Outcomes and treatment patterns in patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy JC Zurko, N Epperla, I Nizamuddin, P Torka, KA David, TA Ollila, BT Hess, ... Blood 138, 884, 2021 | 11 | 2021 |
| Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy R Karmali, R Machhi, N Epperla, G Shouse, J Romancik, TK Moyo, ... Blood Advances 8 (10), 2592-2599, 2024 | 10 | 2024 |
| Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy J Zurko, G Shouse, P Torka, TK Moyo, JT Romancik, IA Nizamuddin, ... Blood 140 (Supplement 1), 375-377, 2022 | 7 | 2022 |
| Older adults with newly diagnosed AML: hot topics for the practicing clinician C Lai, RS Bhansali, EJ Kuo, G Mannis, RJ Lin American Society of Clinical Oncology Educational Book 43, e390018, 2023 | 5 | 2023 |
| Caspase-1 inhibition ameliorates murine acute graft versus host disease by modulating the Th1/Th17/Treg balance W Chen, GZ Su, Y Xu, W Guo, R Bhansali, B Pan, QL Kong, H Cheng, ... International Immunopharmacology 94, 107503, 2021 | 5 | 2021 |
| SOHO state of the art updates and next questions| challenging cases in rare T-cell lymphomas RS Bhansali, SK Barta Clinical Lymphoma Myeloma and Leukemia 23 (9), 642-650, 2023 | 4 | 2023 |
| Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T‐Cell Lymphoma DM Weiner, S Rastogi, DJ Lewis, L Cohen, S Choi, CC Vittorio, PL Haun, ... Dermatologic Therapy 2023 (1), 7625926, 2023 | 4 | 2023 |
| STAT3 Is Activated By DYRK1A and Is a Potential Therapeutic Target in B-ALL M Rammohan, RS Bhansali, YC Tsai, A Dong, S Malinge, JP Bourquin, ... Blood 132, 3898, 2018 | 4 | 2018 |
| Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy Y Wang, MC Larson, SR Hwang, A Kumar, A Joseph, BT Hill, TR Brooks, ... Blood 142, 300, 2023 | 3 | 2023 |
| Central nervous system progression/relapse in mature T-and NK-cell lymphomas RS Bhansali, SK Barta Cancers 15 (3), 925, 2023 | 3 | 2023 |
| Usage and safety of topical tacrolimus in patients with mycosis fungoides DM Weiner, AK Clark, RS Bhansali, L Pappas‐Taffer, SK Barta, ... Clinical and Experimental Dermatology 47 (6), 1200-1201, 2022 | 3 | 2022 |
Thierry BESSONProfesseur Chimie Thérapeutique, Université de Rouen-NormandieVerifierad e-postadress på univ-rouen.fr
